3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Squamous Cell Carcinoma of Head and Neck
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Pancreatic Adenocarcinoma
1
PD-L1-selected Solid Tumors
1
Neoplasm Metastasis
1
Melanoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Carboplatin
49
Etoposide
46
Cisplatin
42
Topotecan
39
Irinotecan
21
Paclitaxel
20
Nivolumab
15
pembrolizumab
13
Gemcitabine
13
atezolizumab
11
Ipilimumab
11
durvalumab
9
Radiotherapy
9
Doxorubicin
7
Bevacizumab
7
rovalpituzumab tesirine
6
etoposide phosphate
6
amrubicin
6
Psychiatric Rehabilitation
6
PM 01183
6
Docetaxel
6
Counseling
6
trilaciclib
5
Temozolomide
5
Sunitinib
5
Platinum
5
Imatinib Mesylate
5
Cyclophosphamide
5
Bortezomib
5
130-nm albumin-bound paclitaxel
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Small Cell Lung Carcinoma
×
Tiragolumab
×
Clear all
NCT04256421
2026-04-03
SKYSCRAPER-02
Hoffmann-La Roche
Phase 3
Completed
490 enrolled
33 charts